Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer.
“Zentalis is sharply focused on our goal of bringing azenosertib to patients with gynecological malignancies,” said Julie Eastland, Chief Executive Officer. “To support this goal, we are continuing to tune our leadership team and today announced the appointment of two talented leaders with a strong track record of successfully supporting organizations through transitional periods. I look forward to working with Wendy, Haibo, and the rest of the leadership team as we advance the development of azenosertib.”
Executive Biographies
Wendy Chang, Chief People Officer
Wendy is the Chief People Officer of Zentalis. She brings over two decades of biopharma experience, including senior roles in human resources and an extensive background in aligning talent with organizations’ overall vision and direction. She was previously Chief People Officer at Harpoon Therapeutics. Before Harpoon, she was VP, Head of People & Culture for IDbyDNA. Wendy previously served in roles of increasing responsibility at Gilead Sciences from 2003 to 2020, most recently as Vice President, Human Resources, and, earlier in her career, at Bio-Rad Laboratories. She received a B.S. in accounting and business/management from the University of California, Riverside, and completed the Global Fellow of Talent Management program at The Wharton School of the University of Pennsylvania.
Haibo Wang, Chief Business Officer
Haibo is the Chief Business Officer of Zentalis. He brings over 15 years of biopharma business development, finance, and M&A transaction experience, having most recently served as Senior Vice President of Business Development at Harpoon Therapeutics. While at Harpoon, he played a pivotal role in managing the Company’s acquisition by Merck, which was completed in March 2024. Prior to Harpoon, he served as the Vice President of Business Development at Hummingbird Bioscience, where he was responsible for the company’s end-to-end business development activities. Prior to Hummingbird, Haibo was Director of Business Development at Amgen, where he played a major role in the Teneobio and Five Prime Therapeutics acquisitions, the oncology collaboration with BeiGene, and many clinical collaborations to advance Amgen’s oncology pipeline. He began his career as an M&A consultant at Deloitte, advising on transactions in healthcare and technology. Haibo holds an M.S. in Biotechnology from Johns Hopkins University, an MBA from Duke University, and a BBA from Tsinghua University.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate, azenosertib (ZN-c3), is a potentially first-in-class and best-in-class WEE1 inhibitor for advanced solid tumors. Azenosertib is being evaluated as a monotherapy and in combination across multiple clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. As part of its azenosertib clinical development program, the Company is exploring enrichment strategies targeting tumors of high genomic instability, such as Cyclin E1 positive tumors, homologous recombination deficient tumors and tumors with oncogenic driver mutations. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in San Diego.
